Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases
- PMID: 21909081
- DOI: 10.1038/modpathol.2011.134
Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases
Abstract
Postradiation cutaneous vascular lesions after treatment of breast carcinoma comprise a heterogeneous group of benign, atypical, and malignant lesions and are best regarded as points along a morphological spectrum. We analyzed a series of cutaneous angiosarcomas after treatment of breast cancer in comparison with control cases and cases of atypical vascular lesions with special emphasis on the expression and amplification of MYC. The 66 cases were divided into control cases (5), cases in which a slight vascular proliferation was seen after radiotherapy of breast cancer (12), cases of atypical vascular lesions after radiotherapy (16), cases of postradiation cutaneous angiosarcomas (25), and cases of angiosarcomas of skin and soft tissues unrelated to radiotherapy (8). None of the control cases (2 M, 3 F, 20-76 years), of cases showing slight vascular proliferation, dermal fibrosis and inflammation after radiotherapy of breast cancer (12 F, 48-79 years), of cases of atypical vascular lesions after radiotherapy (16 F, 29-81 years), and of cases of angiosarcomas of skin and soft tissues unrelated to radiotherapy (3 M, 5 F, 25-92 years) showed an amplification of MYC by FISH analysis. In striking contrast, in all cases of postradiation cutaneous angiosarcomas (25 F, 46-95 years), MYC amplification was found by FISH analysis in a variable number of counted nuclei. Immunohistochemically, strong positive nuclear staining for MYC and prox-1 was seen in cases of postradiation cutaneous angiosarcoma, whereas control cases and cases of atypical vascular proliferation after radiotherapy were negative for MYC, and stained only focally positive for prox-1 in a number of cases. In conclusion, the presence of MYC amplification represents an important additional diagnostic tool in the distinction of postradiation cutaneous angiosarcomas from atypical vascular lesions after radiotherapy. Immunohistochemical stainings for MYC are useful for mapping of these lesions and for careful tumor margin control.
Comment in
-
[MYC amplification distinguishes between atypical vascular lesion and radiation-induced angiosarcoma of the breast].Hautarzt. 2013 Jul;64(7):533-4. doi: 10.1007/s00105-013-2602-5. Hautarzt. 2013. PMID: 23744032 German. No abstract available.
Similar articles
-
MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study.Mod Pathol. 2014 Apr;27(4):509-15. doi: 10.1038/modpathol.2013.163. Epub 2013 Oct 4. Mod Pathol. 2014. PMID: 24091875
-
[MYC amplification distinguishes between atypical vascular lesion and radiation-induced angiosarcoma of the breast].Hautarzt. 2013 Jul;64(7):533-4. doi: 10.1007/s00105-013-2602-5. Hautarzt. 2013. PMID: 23744032 German. No abstract available.
-
Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression.Breast Cancer Res Treat. 2015 May;151(1):131-40. doi: 10.1007/s10549-015-3379-2. Epub 2015 Apr 19. Breast Cancer Res Treat. 2015. PMID: 25893585 Clinical Trial.
-
MYC gene amplification by fluorescence in situ hybridization and MYC protein expression by immunohistochemistry in the diagnosis of cutaneous angiosarcoma: Systematic review and appropriate use criteria.J Cutan Pathol. 2021 Apr;48(4):578-586. doi: 10.1111/cup.13912. Epub 2020 Nov 16. J Cutan Pathol. 2021. PMID: 33128474
-
Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma.Am J Clin Pathol. 1994 Dec;102(6):757-63. doi: 10.1093/ajcp/102.6.757. Am J Clin Pathol. 1994. PMID: 7801888 Review.
Cited by
-
A rare case of radiation-induced breast angiosarcoma: a case report.Case Reports Plast Surg Hand Surg. 2023 Dec 24;11(1):2296697. doi: 10.1080/23320885.2023.2296697. eCollection 2024. Case Reports Plast Surg Hand Surg. 2023. PMID: 38179209 Free PMC article.
-
Radiation-Associated Angiosarcoma of the Breast: The State of the Art of a Rare and Aggressive Disease.J Pers Med. 2024 Aug 14;14(8):859. doi: 10.3390/jpm14080859. J Pers Med. 2024. PMID: 39202050 Free PMC article. Review.
-
Reduced H3K27me3 expression in radiation-associated angiosarcoma of the breast.Virchows Arch. 2018 Mar;472(3):361-368. doi: 10.1007/s00428-017-2242-8. Epub 2017 Oct 5. Virchows Arch. 2018. PMID: 28983701
-
Stewart-Treves syndrome in a spinal cord injury patient with MYC amplification.JAAD Case Rep. 2017 Nov 6;3(6):515-518. doi: 10.1016/j.jdcr.2017.07.004. eCollection 2017 Nov. JAAD Case Rep. 2017. PMID: 29264380 Free PMC article. No abstract available.
-
Neoadjuvant chemotherapy for radiation associated angiosarcoma (RAAS) of the breast: A retrospective single center study.Breast. 2024 Dec;78:103825. doi: 10.1016/j.breast.2024.103825. Epub 2024 Oct 21. Breast. 2024. PMID: 39476458 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical